Indications & formulation #
ADHD in adults; not an extended-release conversion guide. This reference covers the selected formulation; other indications and products need their own evidence.
Dose reference #
Adult educational reference · RITALIN immediate-release oral tablet · United States. The clinician selects treatment after assessment; this page does not calculate or change a prescription.
Selected adult label describes average 20–30 mg/day in two or three doses, preferably before meals; maximum 60 mg/day. Individualize initiation and titration.
Contraindications & important cautions #
Avoid MAOIs and serious cardiac disease. Assess misuse/diversion, blood pressure, pulse, tics and new psychotic/manic symptoms.
Selected important cautions; consult the full product information for all contraindications and warnings.
Adverse effects #
Appetite suppression, insomnia, pulse/BP changes and misuse risk.
Interactions #
MAOIs are contraindicated; review other sympathomimetics.
Monitoring #
Track function, blood pressure/pulse, weight, sleep and misuse/diversion.
Special populations #
Review weight, appetite and sleep; pregnancy requires individual assessment. Other release formulations have different exposure profiles.
Adult scope. Pregnancy, breastfeeding and pediatric use require the exact product’s population-specific guidance and individual assessment.
Discontinuation, restarting & counseling #
Reassess functioning, mood and withdrawal symptoms when reducing or stopping; secure storage matters.
Condition-specific prescribing #
Additional indication-specific records retain their own formulation and source context.
Methylphenidate
Adult ADHD; new to methylphenidate
Adults up to 65 years under the cited US label · CONCERTA extended-release tablet; not interchangeable instructions for all methylphenidate products · Oral · US FDA CONCERTA label, 2026; no Indian product equivalence assumed
- Starting dose
- 18 mg or 36 mg once each morning.
- Titration
- Increase by 18 mg at weekly intervals according to response and tolerability.
- Treatment range / target
- 18–72 mg once daily.
- Maximum / limits
- 72 mg/day under this adult product label.
- Trial & duration
- Periodically reassess continuing benefit; dose optimization is guided by symptoms and functioning.
- Monitoring
- Blood pressure, pulse, weight/appetite, sleep, psychiatric effects and misuse/diversion.
- Population & organ-function adjustments
- Existing immediate-release treatment requires the product conversion table; do not substitute mg-for-mg automatically.
- Important cautions
- Swallow whole. Avoid in serious cardiac disease; contraindicated with MAO inhibitors or within 14 days of stopping them.
Brands & products #
Historical catalogue observations. Prices and catalogue presence do not establish current availability or Indian approval.
Reference coverage #
Structured summary of selected adult uses, not an exhaustive monograph. Indian product authorization and local prescribing requirements have not been reconciled.
References · 2
- Methylphenidate — RITALIN immediate-release oral tablet — selected prescribing information · United States · Checked 2026-10-27 · Selected formulation: RITALIN immediate-release oral tablet · Supports indications, dose, cautions, adverse effects, interactions, monitoring, special populations and stopping. Source sections: Indications and usage; Dosage and administration; Contraindications; warnings and precautions; Use in specific populations; patient counseling
- FDA: CONCERTA prescribing information, 2026 · United States label · Checked 2026-10-26 · Supports: Methylphenidate — Adult ADHD; new to methylphenidate (CONCERTA extended-release tablet; not interchangeable instructions for all methylphenidate products)